Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks.

TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described the five-year revenue outlook as “attractive” and stated that the stock is “poised for a breakout” after accretive M&A and ahead of a catalyst-rich era after integrating MRK’s late-stage pipeline, possible label expansions, and prescriber feedback into its models.

Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion

Separately, on January 9, reports emerged that MRK is in active talks to acquire Revolution Medicines for approximately $30 billion.

Merck & Co., Inc. (NYSE:MRK) is a leading oncology company driven by its blockbuster immunotherapy Keytruda, with a diversified cancer portfolio spanning immuno-oncology, targeted therapies, and combination regimens, supported by an expanding clinical pipeline and strategic acquisitions to sustain long-term growth.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.